{
    "Trade/Device Name(s)": [
        "Amylase2"
    ],
    "Submitter Information": "Abbott Ireland Diagnostics Division",
    "510(k) Number": "K210633",
    "Predicate Device Reference 510(k) Number(s)": [
        "K981653"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "JFJ"
    ],
    "Summary Letter Date": "March 29, 2022",
    "Summary Letter Received Date": "March 29, 2022",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.1070"
    ],
    "Regulation Name(s)": [
        "Amylase Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Amylase"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma",
        "Urine"
    ],
    "Specimen Container(s)": [
        "Serum tube",
        "Serum separator tube",
        "Lithium heparin tube",
        "Lithium heparin separator tube",
        "Sodium heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "ARCHITECT c System"
    ],
    "Method(s)/Technology(ies)": [
        "Enzymatic",
        "Colorimetric"
    ],
    "Methodologies": [
        "Enzymatic/Colorimetric quantitation"
    ],
    "Submission Type(s)": [
        "Reagent",
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for Abbott Amylase2 automated clinical chemistry assay for quantitation of amylase on the ARCHITECT c System.",
    "Indications for Use Summary": "For quantitation of amylase in human serum, plasma, or urine as an aid in the diagnosis and treatment of pancreatitis.",
    "fda_folder": "Clinical Chemistry"
}